MP60-02 TRANSCRIPTOMICS CAN PREDICT HOMOLOGOUS RECOMBINATION DEFICIENCY IN PROSTATE CANCER

You have accessJournal of UrologyProstate Cancer: Markers (MP60)1 Sep 2021MP60-02 TRANSCRIPTOMICS CAN PREDICT HOMOLOGOUS RECOMBINATION DEFICIENCY IN PROSTATE CANCER Adam Weiner, Yang Liu, Matthew McFarlane, Pushpinder Bawa, Eric Li, Xin Zhao, Ziwen Tanya Hammoud, Munna Hazime, R. Jeffrey Karnes, Elai Davicioni, Zachery Reichert, Arul Chinnaiyan, Tamara Lotan, and Edward Schaeffer WeinerAdam Weiner More articles by this author , LiuYang Liu McFarlaneMatthew McFarlane BawaPushpinder Bawa LiEric Li ZhaoXin Zhao LiZiwen HammoudTanya Hammoud HazimeMunna Hazime KarnesR. Karnes DavicioniElai Davicioni ReichertZachery Reichert ChinnaiyanArul Chinnaiyan LotanTamara Lotan SchaefferEdward View All Author Informationhttps://doi.org/10.1097/JU.0000000000002095.02AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Tumors with mutations associated homologous recombination deficiency (HRD) are uncommon in prostate cancer (PCa) variably responsive PARP inhibition. To better identify tumors HRD, we developed validated a transcriptomic signature for HRD PCa (HRD-P). METHODS: By using an established mutational tumor created 16-gene HRD-P six independent cohorts (primary PCa, n=8,224; metastatic castrate-resistant [mCRPC], n=328). Molecular clinical features were compared between HRD-P+ those single HR-gene that would qualified patients recent inhibitor trials mCRPC. RESULTS: more numerous than primary (201/491, 41% vs 32/491 6.5%; Figure 1) mCRPC (126/328, 38% 82/328, 25%) cases was predictive genomic instability suggestive HRD. shorter time recurrence following surgery overall survival men (Figure 2). In prospective trial treated olaparib (n=10), all three experienced prolonged (>330 days) PSA progression-free survival. CONCLUSIONS: These results suggest transcriptomics can harbor phenotypic support further exploration transcriptionally defined perhaps conjunction markers therapeutic application. Source Funding: This work supported part the National Institutes Health grant 5U01CA196390 (EMS), Prostate Cancer Foundation Department Defense W81XWH-15-1-0661 (EMS TLL), 2019 Urology Care Residency Research Award Program Russell Scott, Jr., MD Fund (ABW), as well University Michigan Specialized Excellence (SPORE) P50 CA186786-05 Early Detection Network UO1 CA111275 (AMC). © 2021 American Urological Association Education Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e1041-e1041 Advertisement Copyright & Permissions© Inc.MetricsAuthor Information Expand Loading ...